Literature DB >> 15492472

Herpes simplex virus type 2 infection is a risk factor for hypertension.

Yuhua Sun1, Weidong Pei, Yongjian Wu, Zhicheng Jing, Jian Zhang, Guogan Wang.   

Abstract

Herpes simplex virus type 2 (HSV-2), which has been recognized as a potential cardiovascular pathogen and implicated in carotid atherosclerosis and coronary artery disease, is independently associated with the future risk of cardiovascular death. Investigations have demonstrated that hypertension may be related to inflammation, and inflammation is one of the symptoms of HSV-2 infection. This cross-sectional study investigated the correlation between HSV-2 infection and essential hypertension. One thousand two hundred and forty four inpatients (488 patients with essential hypertension and 756 normotensives) were investigated serologically for the specific immunoglobulin G (IgG) to HSV-2 by enzyme-linked immunosorbent assay. Patients diagnosed with pheochromocytoma, primary aldosteronism, aorto-arteritis or renal artery stenosis were excluded. The prevalence of HSV-2 IgG seropositivity was significantly higher in the hypertensive group than in the normotensive group (38.3% vs. 29.8%, p =0.002). After adjustment for confounding factors, an association of HSV-2 IgG seropositivity with essential hypertension was found on binary logistic regression analysis. The adjusted odds ratio of essential hypertension was 1.4 (95% confidence intervals, 1.1 to 1.8; p =0.005) for HSV-2 infection; the adjusted covariates included age, male sex, smoking, body mass index, dyslipidemia, diabetes and coronary artery disease. The results of this study indicated that HSV-2 infection might be an independent risk factor for essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492472     DOI: 10.1291/hypres.27.541

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  8 in total

1.  Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study.

Authors:  Rulin C Hechter; Matthew Budoff; Howard N Hodis; Charles R Rinaldo; Frank J Jenkins; Lisa P Jacobson; Lawrence A Kingsley; Babafemi Taiwo; Wendy S Post; Joseph B Margolick; Roger Detels
Journal:  Atherosclerosis       Date:  2012-03-14       Impact factor: 5.162

2.  Association of hypertension with helicobacter pylori: A systematic review and meta‑analysis.

Authors:  Yizhen Fang; Huabin Xie; Chunming Fan
Journal:  PLoS One       Date:  2022-05-19       Impact factor: 3.752

Review 3.  Infectious and coronary artery disease.

Authors:  Mohammad Saeid Rezaee-Zavareh; Mohammad Tohidi; Amin Sabouri; Mahdi Ramezani-Binabaj; Mohsen Sadeghi-Ghahrodi; Behzad Einollahi
Journal:  ARYA Atheroscler       Date:  2016-01

Review 4.  Viral infection and atherosclerosis.

Authors:  Nima Hemmat; Amin Ebadi; Reza Badalzadeh; Mohammad Yousef Memar; Hossein Bannazadeh Baghi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-05       Impact factor: 3.267

Review 5.  Sympathetic-mediated activation versus suppression of the immune system: consequences for hypertension.

Authors:  Adam J Case; Matthew C Zimmerman
Journal:  J Physiol       Date:  2015-12-30       Impact factor: 5.182

6.  Unpacking the 'black box' of total pathogen burden: is number or type of pathogens most predictive of all-cause mortality in the United States?

Authors:  A M Simanek; J B Dowd; A Zajacova; A E Aiello
Journal:  Epidemiol Infect       Date:  2014-12-18       Impact factor: 4.434

Review 7.  Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus.

Authors:  Luis M Beltrán; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Jesús Egido; Juan García-Puig; Juan Antonio Moreno
Journal:  Vasc Health Risk Manag       Date:  2015-01-06

8.  Fetal exposure to herpesviruses may be associated with pregnancy-induced hypertensive disorders and preterm birth in a Caucasian population.

Authors:  C S Gibson; P N Goldwater; A H MacLennan; E A Haan; K Priest; G A Dekker
Journal:  BJOG       Date:  2008-03       Impact factor: 6.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.